TITLE 42
State Affairs and Government
CHAPTER 42-66.2
Pharmaceutical Assistance to the Elderly Act
SECTION 42-66.2-10
§ 42-66.2-10 Pharmaceutical manufacturer
drug rebates.
(a) The director shall enter into prescription drug rebate agreements with
individual pharmaceutical manufacturers under which the department shall
receive a rebate from the pharmaceutical manufacturer equal to the basic rebate
supplied by the manufacturer under 42 U.S.C. § 1396a for every eligible
prescription drug dispensed under the program. Each prescription drug rebate
agreement shall provide that the pharmaceutical manufacturer shall make
quarterly rebate payments to the department equal to the basic rebate supplied
by the manufacturer under 42 U.S.C. § 1396a for the total number of dosage
units of each form and strength of a prescription drug which the department
reports as reimbursed to providers of prescription drugs, provided these
payments shall not be due until thirty (30) days following the manufacturer's
receipt of utilization data from the department including the number of dosage
units reimbursed to providers of eligible prescription drugs during the quarter
for which payment is due.
(b)(1) Upon receipt of the utilization data from the
department, the pharmaceutical manufacturer shall calculate the quarterly
payment. The department may, at its expense, hire a mutually agreed upon
independent auditor to verify the calculation and payment. In the event that a
discrepancy is discovered between the pharmaceutical manufacturer's calculation
and the independent auditor's calculation, the pharmaceutical manufacturer
shall justify its calculations or make payment to the department for any
additional amount due.
(2) The pharmaceutical manufacturer may, at its expense, hire
a mutually agreed upon independent auditor to verify the accuracy of the
utilization data provided by the department. In the event that a discrepancy is
discovered, the department shall justify its data or refund any excess payment
to the pharmaceutical manufacturer. The department may, at its expense,
establish a grievance adjudication procedure, which provides for independent
review of manufacturer documentation substantiating the basic rebate amount per
unit delivered under 42 U.S.C. § 1396a. In the event that a discrepancy is
discovered, the department shall justify its data or refund any excess payment
to the pharmaceutical manufacturer.
(c) All eligible prescription drugs of a pharmaceutical
manufacturer that enters into an agreement pursuant to subsection (a) shall be
immediately available and the cost of these eligible drugs shall be reimbursed
and not subject to any restrictions or prior authorization requirements. Any
prescription drug of a manufacturer that does not enter into an agreement
pursuant to subsection (a) shall not be reimbursable, unless the department
determines the eligible prescription drug is essential to program participants.
(d) All rebates collected by the department from the rebate
payments made for drugs for persons eligible under the provisions of §
42-66.2-5(a) shall be deposited in a restricted receipt account, hereby created
within the agency and known as Pharmaceutical Rebates, to pay costs in
accordance with the provisions of § 42-66.2-4.
History of Section.
(P.L. 1992, ch. 15, art. 8, § 3; P.L. 1992, ch. 133, art. 52, § 1;
P.L. 1995, ch. 370, art. 40, § 141; P.L. 2002, ch. 65, art. 37, § 1;
P.L. 2005, ch. 117, art. 22, § 1.)